| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| ln Vitro |
Orexin A acetate from humans, rats, and mice (0.1, 1, 10, 100 nM; 24 h) increased the expression of BDNF in SH-SY5Y human dopaminergic neuroblastoma cells in a dose-dependent manner [1]. Orexin A acetate from humans, rats, and mice (1 nM; 1, 3, 6, 12, 24 h) increased the expression of BDNF, TH, and PI3K in SH-SY5Y cells in a time-dependent manner [1].
|
|---|---|
| ln Vivo |
Orexin A acetate from human, rat, and mouse (300 ng/mouse; intraventricular injection; once daily for 8 consecutive days) can reduce the loss of dopaminergic neurons and the decrease in tyrosine hydroxylase (TH) expression in the substantia nigra, restore striatal dopaminergic fibers to normal, and prevent the depletion of dopamine and its metabolites in the striatum [1]. Orexin A acetate from human, rat, and mouse (10, 30 mg/kg; intravenous injection; single dose) showed analgesic effects in carrageenan-induced thermal hyperalgesia model and PPQ-induced abdominal writhing model in mice [2].
|
| Cell Assay |
Western Blot Analysis [1]
Cell Types: SH-SY5Y cells Tested Concentrations: 0.1, 1, 10, 100 nM Incubation Duration: 24 hours Experimental Results: PI3K and TH expression increased in a dose-dependent manner. BDNF expression was significantly induced at concentrations of 1 nM and 10 nM. Western Blot Analysis [1] Cell Types: SH-SY5Y cells Tested Concentrations: 1 nM Incubation Duration: 1, 3, 6, 12, 24 hours Experimental Results: PI3K expression increased rapidly by 72.6% within 3 hours and remained at a high level for the next 24 hours. BDNF protein levels increased by 44.8%, and TH protein levels increased significantly by 48.5% within 12 hours. |
| Animal Protocol |
Animal/Disease Models:Male C57BL/6 mice (10 weeks old; 22-26 g; MPTP-induced Parkinson's disease mouse model) [1].
Doses: 300 ng/mouse Route of Administration: Intraventricular injection; once daily for 8 consecutive days Experimental Results: OX1R reversed MPTP-induced motor dysfunction and increased BDNF protein expression in substantia nigra dopaminergic neurons. It improved MPTP-induced spatial learning and memory impairment and protected dopaminergic neurons from MPTP-induced neurotoxic damage. It alleviated the reduction of substantia nigra dopaminergic neurons and restored the reduction of striatal dopaminergic fibers. Animal/Disease Models:Female ICR mice (17-28 g; carrageenan-induced thermal hyperalgesia model) [2]. Doses: 10, 30 mg/kg. Route of Administration: Intravenous injection; single dose; pre-test 5 minutes. Experimental Results: The paw withdrawal latency to thermal stimulation was prolonged to baseline. Animal/Disease Models:Male ICR mice (17-20 g; phenyl-p-quinone (PPQ) induced mouse abdominal writhing model) [2]. Doses: 3, 10, 30 mg/kg. Route of Administration: Intravenous injection; single dose; immediately before PPQ administration. Experimental Results: The latency of the first writhing induced by PPQ increased from 357.4 s (blank control group) to 500.3 s in the 10 mg/kg dose group and 594.5 s in the 30 mg/kg dose group. |
| References |
| Molecular Formula |
C152H243N47O44S4.XC2H4O2
|
|---|---|
| Molecular Weight |
3561.10 (free base)
|
| Related CAS # |
Orexin A (human, rat, mouse); Orexin A (human, rat, mouse) TFA
|
| Sequence |
{Glp}-Pro-Leu-Pro-Asp-Cys-Cys-Arg-Gln-Lys-Thr-Cys-Ser-Cys-Arg-Leu-Tyr-Glu-Leu-Leu-His-Gly-Ala-Gly-Asn-His-Ala-Ala-Gly-Ile-Leu-Thr-Leu-NH2 (Disulfide bridge: Cys6-Cys12, Cys7-Cys14){Glp}-PLPDCCRQKTCSCRLYELLHGAGNHAAGILTL-NH2 (Disulfide bridge: Cys6-Cys12, Cys7-Cys14)
|
| SequenceShortening |
{Glp}-PLPDCCRQKTCSCRLYELLHGAGNHAAGILTL-NH2 (Disulfide bridge: Cys6-Cys12, Cys7-Cys14)
|
| Appearance |
White to off-white solid
|
| Synonyms |
Hypocretin-1 (human, rat, mouse) acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: 请将本产品存放在密封且受保护的环境中（例如氮气下），避免暴露在潮湿和光照下。 |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 50 mg/mL
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
